Aledort L - Search Results

1

The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.

Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L. Kurth M, et al. Among authors: aledort l. J Thromb Haemost. 2011 Nov;9(11):2229-34. doi: 10.1111/j.1538-7836.2011.04493.x. J Thromb Haemost. 2011. PMID: 21883884 Free article.

2

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, Patrone L, Wong WY; Prophylaxis Study Group. Valentino LA, et al. J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x. J Thromb Haemost. 2012. PMID: 22212248 Free PMC article. Clinical Trial.

3

Therapeutic choices for patients with hemophilia and high-titer inhibitors.

Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, Cohen AR, Ewing NP, Gringeri A, Gruppo R, Hoots K, Leissenger C, Peerlinck K, Poon MC, Wong WY. Kulkarni R, et al. Among authors: aledort lm. Am J Hematol. 2001 Aug;67(4):240-6. doi: 10.1002/ajh.1123. Am J Hematol. 2001. PMID: 11443636 Free article. Review.

4

Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.

Aledort LM, Navickis RJ, Wilkes MM. Aledort LM, et al. J Thromb Haemost. 2011 Nov;9(11):2180-92. doi: 10.1111/j.1538-7836.2011.04472.x. J Thromb Haemost. 2011. PMID: 21848690 Free article.

5

Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment.

Aledort LM. Aledort LM. J Thromb Haemost. 2011 Mar;9(3):423-7. doi: 10.1111/j.1538-7836.2010.04169.x. J Thromb Haemost. 2011. PMID: 21143382 Free article. Review.

6

Emerging clinical concerns in the ageing haemophilia patient.

Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B. Konkle BA, et al. Among authors: aledort l. Haemophilia. 2009 Nov;15(6):1197-209. doi: 10.1111/j.1365-2516.2009.02066.x. Epub 2009 Jul 21. Haemophilia. 2009. PMID: 19686466 Review.

7

von Willebrand disease: from the bedside to therapy.

Aledort LM. Aledort LM. Thromb Haemost. 1997 Jul;78(1):562-5. Thromb Haemost. 1997. PMID: 9198216 Review.

8

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.

Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Key NS, et al. Among authors: aledort lm. Thromb Haemost. 1998 Dec;80(6):912-8. Thromb Haemost. 1998. PMID: 9869160 Clinical Trial.

9

Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.

Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E. Oldenburg J, et al. Among authors: aledort lm. Haemophilia. 2014 Jan;20(1):83-91. doi: 10.1111/hae.12263. Epub 2013 Nov 19. Haemophilia. 2014. PMID: 24354480 Free article.

10

Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.

Rivard GE, Aledort L; Alphanate Surgical Investigators. Rivard GE, et al. Among authors: aledort l. Haemophilia. 2008 Mar;14(2):271-5. doi: 10.1111/j.1365-2516.2007.01616.x. Epub 2008 Jan 8. Haemophilia. 2008. PMID: 18194310

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters